ERBA Diagnostics, Inc. Appoints William Creech as Vice President Sales and Marketing

ERBA Diagnostics, Inc. Appoints William Creech as Vice President Sales and
Marketing

MIAMI LAKES, Fla., June 20, 2014 (GLOBE NEWSWIRE) -- ERBA Diagnostics, Inc.
(NYSE MKT:ERB), a fully integrated in vitro diagnostics company, has appointed
William Creech as Vice President Sales and Marketing.

Mr. Creech has over 20 years of successful experience in the diagnostics
industry. His last assignment was with Vermillion Inc., a diagnostics company,
as Vice President Sales and Marketing, leading the commercialization of a
novel test for ovarian cancer. Prior to that, Mr. Creech worked in various
capacities of increasing responsibilities with Abbott Laboratories Diagnostics
Division, Siemens Healthcare and Thermo Fisher Scientific, where he was VP
Sales and Marketing, Capitol Vial subsidiary.

Mohan Gopalkrishnan, Chief Executive Officer of ERBA Diagnostics, said, "Mr.
Creech is a key addition to our management team and will focus on building a
strong sales and marketing organization to deliver our growth objectives. We
expect that his rich experience and knowledge of the diagnostics industry will
add to our strategic focus in product development and future acquisitions."

About ERBA Diagnostics, Inc.

ERBA Diagnostics, Inc. (www.erbadiagnostics.com), headquartered in Miami
Lakes, Florida, is a fully integrated in vitro diagnostics company that
develops, manufactures and distributes in the United States and
internationally, proprietary diagnostic reagents, test kits and
instrumentation, primarily for autoimmune and infectious diseases, clinical
chemistry, hematology and diabetes through its six subsidiaries – Diamedix
Corporation (U.S.), Delta Biologicals S.r.l. (Europe), ImmunoVision, Inc.
(U.S.), Drew Scientific, Inc. (U.S.), JAS Diagnostics, Inc. (U.S.), and Erba
Diagnostics Mexico S.A. (Latin America).

Safe Harbor Statement

Except for the historical matters contained herein, statements in this press
release are forward-looking and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Investors
are cautioned that forward-looking statements involve risks and uncertainties
that may affect the business and prospects of ERBA Diagnostics, Inc.,
including, without limitation: the risks and uncertainties associated with
ERBA Diagnostics' business strategies, including, without limitation, the risk
Mr. Creech's appointment may not build a strong sales and marketing
organization, achieve growth objectives or increase focus in product
development and future acquisitions, or otherwise; the risk Mr. Creech's
appointment may not have a positive impact on ERBA Diagnostics' business
strategies and may not be successful in ERBA Diagnostics achieving improved
sales or operating results; and other risks and uncertainties that may cause
results to differ materially from those set forth in the forward-looking
statements. In addition to the risks and uncertainties set forth above,
investors should consider the economic, competitive, governmental,
technological and other risks and uncertainties discussed in ERBA Diagnostics'
filings with the Securities and Exchange Commission, including, without
limitation, the risks and uncertainties discussed under the heading "Risk
Factors" in such filings.

CONTACT: Company Contact:
         Mohan Gopalkrishnan
         Chief Executive Officer
         Tel: 305 418 2320 x 319
 
Press spacebar to pause and continue. Press esc to stop.